All posts tagged "Biomimetic"

  • Biologics
    3D printing steers walking bio-bots to march of progress

    Biomimetics—the use of designs and systems found in nature to inspire engineering solutions—has been a fertile field...

  • Biologics
    FDA approval of BioMimetic’s Augment Bone Graft dependent on more information

    In a post-panel response letter, the FDA told BioMimetic Therapeutics Inc. that it would need to submit more information about the safety and efficacy of its Augment Bone Graft in order to receive premarket approval. According to a press release, the additional information requested by the FDA from the Augment pivotal study...

  • Biologics
    FDA seeks more info from BioMimetic

    BioMimetic Therapeutics Inc. (Nasdaq: BMTI) was dealt a setback Tuesday when it learned the Food and Drug Administration    did not approve its application for the bone graft device Augment, and has requested additional clinical information from the company. BioMimetic had been aiming for FDA approval of the device by the end of 2011. But the Nashville-based...

  • Biologics
    BioMimetic Therapeutics’ Augment™ Bone Graft Receives Positive Recommendation from FDA Advisory Committee

    Franklin, Tenn. – May 12, 2011 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, announced today that the U.S. Food & Drug Administration’s (FDA) Orthopedic and Rehabilitation Devices Panel of the Medical...

  • Biologics
    BioMimetic Therapeutics Augment™ Bone Graft Advisory Panel Meeting Date Published in Federal Register

    FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of...

  • Biologics
    Biomimetic patch to be tested on tricky tendon-to-bone repairs

    Group receives more than $2 million to improve surgery for a common shoulder problem IMAGE: A graded biomimetic patch is created in Younan Xia’s laboratory by coating a mat of biocompatible polymers with a mineral solution that contains calcium and phosphate ions at concentrations 10… Click here for more information. Two Washington...

  • Biologics
    BioMimetic Therapeutics, Inc. Highlights Commercial and Product Development Activities during AAOS

    FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced highlights from its analyst and investor meeting which was held on Thursday, February 17 in San Diego, CA in conjunction with the American Academy of Orthopedic Surgery (AAOS) Annual Meeting. The BioMimetic management team provided updates regarding the Company’s May 12, 2011 Orthopedic...

  • Biologics
    BioMimetic Therapeutics Announces Date of FDA Advisory Panel Review of Augment™ Bone Graft

    FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and commercialization of...

  • Biologics
    BioMimetic Therapeutics, Inc. Continues to Enhance Patent Portfolio

    FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today the Canadian Intellectual Property Office (CIPO) has allowed...

  • Sports Medicine
    BioMimetic Therapeutics, Inc. Initiates Augment™ Rotator Cuff Graft Trial

    FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced it initiated enrollment in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears. The randomized, controlled pilot trial is expected to include enrollment of up to 30 patients. The...

  • Biologics
    BioMimetic Therapeutics, Inc. to Present at the Canaccord Genuity Global Growth Conference

    FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Samuel E. Lynch, president and CEO, will provide an update of corporate activities at the Canaccord Genuity 30th Annual Global Growth Conference on Thursday, August 12 at 10:30 a.m. Eastern Time. The presentation will be held in the Toronto Room at...

  • Biologics
    BioMimetic raises $45 million from stock offering, plans to fund product development

    FRANKLIN, Tenn. (AP) – BioMimetic Therapeutics Inc. said it generated about $45 million in proceeds after expenses from the sale of about 5.6 million shares in a public offering. The Franklin, Tenn., biotechnology company, which makes devices for musculoskeletal injuries, said Tuesday that underwriters exercised their option to buy about 642,000 additional...

  • Biologics
    BioMimetic Therapeutics Receives Filing Letter from FDA for Augment™ Bone Graft PMA

    FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced the Food & Drug Administration (FDA) has accepted for review its Premarket Approval (PMA) application for Augment™ Bone Graft for use in foot and ankle fusions in the U.S. The FDA has now filed the application and begun the comprehensive review of the...

  • Financial
    BioMimetic Therapeutics Announces Highlights from 2010 Annual Meeting of Stockholders

    FRANKLIN, Tenn., Jun 17, 2010 (BUSINESS WIRE) — BioMimetic Therapeutics, Inc. (BMTI 12.64, +0.19, +1.53%)today announced the results of its 2010 Annual Meeting of Stockholders that took place on June 17, 2010 at the Company’s headquarters. The Company’s shareholders voted in favor of all proposals identified in the Proxy Statement. Re-elected to the board of...

  • Biologics
    BioMimetic Therapeutics, Inc. to Highlight Pre-Clinical and Clinical Activities at ORS and AAOS Meetings

    FRANKLIN, Tenn.–(BUSINESS WIRE)–BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced its schedule of events at the Orthopedic Research Society (ORS) and the American Academy of Orthopedic Surgeons (AAOS) meetings. These meetings are being held consecutively in New Orleans, LA beginning March 6, 2010. ORS Meeting; March 6 – March 9 The following poster...

OrthoSpineNews is a publication run by Ortho Spine Companies which includes other brands like The De Angelis Group, Ortho Sales Partners, OrthoEx and Surg.io

Our desire is to provide valuable content to the industry we love in an easy to read manner.

Copyright © 2018 OrthoSpineNews.

Themed By teapots